J'nisha Jolani Manibusan
Physician Assistant · Palo Alto, CANPI 1043985856
Payments from drug & device makers
Across 77 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- Novo Nordisk$305
- Lilly USA, LLC$284
- Viiv Healthcare Company$216
- Gilead$142
- GSK$116
- plus $813 from 14 others
What the payments were for
- Food & beverage$2,181100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $305 |
| Novo Nordisk | 11 | $305 |
| Lilly USA, LLC | 10 | $284 |
| Viiv Healthcare Company | 2 | $216 |
| Gilead | 2 | $142 |
| GSK | 2 | $116 |
| Pfizer | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 1 | $109 |
| Organon | 6 | $105 |
| Bayer | 4 | $98 |
| AstraZeneca | 1 | $85 |
| Exact Sciences | 3 | $70 |
| Merck | 3 | $55 |
| Boehringer Ingelheim | 2 | $51 |
| Indivior Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,181 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $34,695 |
| RybelsusSemaglutide | 11 | $13,718 |
| FarxigaDapagliflozin Propanediol | 11 | $8,007 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,662 |
| Atorvastatin Calcium | 79 | $440 |
| Tamsulosin Hcl | 15 | $417 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $338 |
| Losartan Potassium | 49 | $309 |
| Metformin Hcl | 46 | $300 |
| Amlodipine Besylate | 34 | $216 |
| Rosuvastatin Calcium | 12 | $186 |
| Lisinopril | 26 | $154 |
| Pantoprazole Sodium | 20 | $144 |
| Metoprolol Succinate | 14 | $137 |
| Alendronate Sodium | 20 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $51 | $34,69540 claims |
| Novo NordiskRybelsus | $305 | $13,71811 claims |
| AstraZenecaFarxiga | $85 | $8,00711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19 | $5,66212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Palo Alto
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.